Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2010

View Archived Issues

Irinotecan/S-1 active in 5-FU-resistant bladder cancer cell lines

Fast-dissolving desmopressin is safe in adults with nocturia

Two placebo-controlled trials show safety of CX-157

New GABA(A) receptor modulators claimed by NeuroSearch

Merck & Co. discloses new FABP inhibitors

Merck & Co. describes new gamma-secretase modulators

Nycomed presents new PDE4B inhibitors

Arbaclofen placarbil improves sleep quality in PPI-responsive GERD

Antitumor agent MSC-1936369B shows safety in phase I trial

NTx described as biomarker for prediction of bone metastasis in lung cancer

Bortezomib linked to heart failure in patients with multiple myeloma

PTC receives award to develop anticancer drugs targeting BMI-1

Merck Serono resubmits cladribine tablets NDA for relapsing MS to FDA

Benlysta MAA submitted to EMA for SLE

Can-Fite opens new CF-101 IND with phase II/III trial protocol in psoriasis

VIVUS' avanafil improves ED in phase III trial in diabetic men

Auxilium reports 2-year recurrence data on Xiaflex

AVI BioPharma and DTRA enter into new contract for AVI-7100

Phico Therapeutics' PT1.2 safe and well tolerated in phase I trial

Zealand Pharma and sanofi-aventis extend lixisenatide licensing agreement

Telik reports phase II data on ezatiostat in MDS

Adeona advances enrollment in part 2 of CopperProof-2 trial in AD

Immunovaccine and Vaxil join to advance potential cancer vaccine

Cellceutix expedites studies of KM-391 and Kevetrin

Opal Therapeutics and MGH to jointly develop HIV vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...